ReviewFrontiers in endocrinology2026
Diabetic impact on the neuroaxis: from peripheral neuropathy to central neurodegeneration.
Review in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Diabetic neuropathy has typically been viewed as a peripheral nerve disorder, most commonly presenting as distal symmetrical polyneuropathy (DSPN). However, accumulating evidence suggests that diabetes affects not only peripheral somatic and autonomic fibers but also the central nervous system, indicating more widespread neurodegenerative processes. Aim: This narrative review aims to synthesize current knowledge on how diabetes affects the nervous system across the neuroaxis, integrating peripheral, autonomic, and central mechanisms, and to provide an overview of clinical manifestations, diagnostic approaches, and management strategies. Results: Chronic hyperglycemia induces a range of metabolic and vascular disturbances, including oxidative stress, inflammation, and microvascular dysfunction, which contribute to peripheral nerve injury. These changes affect both small and large fibers, leading to sensory loss, neuropathic pain, and motor impairment. Autonomic involvement is common and manifests as cardiovascular, gastrointestinal, sudomotor, urogenital, and ocular dysfunction. Importantly, diabetes-related neural injury extends beyond the peripheral nervous system. Structural and functional alterations have been demonstrated in the spinal cord, brainstem and brain, including changes in white matter integrity, cortical organization, and functional connectivity. Peripheral and central mechanisms interact bidirectionally, contributing to altered sensory processing and pain modulation. Conclusion: Diabetic neuropathy should be understood as a disorder of the entire neuroaxis. Integrating peripheral and central aspects is essential to gain a holistic view of diabetic neuropathy and to support the development of more targeted diagnostic and therapeutic strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.